Invivyd, Inc.
IVVD · Healthcare · $252M
$0.86+0.65%
Price
$0.85
$1.00
Jul 1, 26Sep 30, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$15M+5.3%
6/'26 vs prev quarter
Company Health
Market Cap$252M
Operating Margin-192.8%
Cash on Hand$160M63.5% of market cap
Free Cash Flow$-110M-43.5% of market cap
Among 327 Biotechnology peers
LowMedianHigh
PSR4.3xmedian 11.4xPBR1.4xmedian 2.0xROE-59.3%median -54.5%Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 AntibodyYesterday
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission TranscriptYesterday
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311Yesterday
Invivyd to Participate in Upcoming September Investor ConferencesSep 8
BlackRock Inc. Takes $14.08 Million Position in Invivyd, Inc. $IVVDSep 4
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Sep 3
